Elevation Oncology enters licensing agreement with Synaffix B.V.

Elevation Oncology (ELEV) announced that it has entered into a licensing agreement with Synaffix B.V. This licensing agreement gives Elevation Oncology global access to Synaffix’s clinical stage, site-specific ADC technology platform, including GlycoConnect antibody conjugation technology, HydraSpace polar spacer technology, as well as the toxSYN linker-payload, SYNstatin E. The license granted to GlycoConnect and HydraSpace technologies is exclusive to HER3 as a single target in combination with SYNstatin E linker-payload.